Lindsley F. Kimball Research Institute
Lanying Du has not added Biography.
If you are Lanying Du and would like to personalize this page please email our Author Liaison for assistance.
Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus.
Antiviral therapy , 2005 | Pubmed ID: 15918330
Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine.
Vaccine Jun, 2006 | Pubmed ID: 16725238
Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines.
Virology Sep, 2006 | Pubmed ID: 16793110
Severe acute respiratory syndrome-associated coronavirus 3a protein forms an ion channel and modulates virus release.
Proceedings of the National Academy of Sciences of the United States of America Aug, 2006 | Pubmed ID: 16894145
Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.
Vaccine Apr, 2007 | Pubmed ID: 17092615
Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity.
Biochemical and biophysical research communications Jul, 2007 | Pubmed ID: 17533109
Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.
Journal of immunology (Baltimore, Md. : 1950) Jan, 2008 | Pubmed ID: 18178835
Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection.
Vaccine Mar, 2008 | Pubmed ID: 18289745
Development of subunit vaccines against severe acute respiratory syndrome.
Drugs of today (Barcelona, Spain : 1998) Jan, 2008 | Pubmed ID: 18301805
Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines.
Vaccine Sep, 2008 | Pubmed ID: 18675867
The spike protein of SARS-CoV--a target for vaccine and therapeutic development.
Nature reviews. Microbiology Mar, 2009 | Pubmed ID: 19198616
Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells.
Biochemical and biophysical research communications Jul, 2009 | Pubmed ID: 19422787
Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity.
Virology Oct, 2009 | Pubmed ID: 19683779
Research and development of universal influenza vaccines.
Microbes and infection / Institut Pasteur Apr, 2010 | Pubmed ID: 20079871
An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses.
Virology journal , 2010 | Pubmed ID: 20082709
A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity.
Viral immunology Apr, 2010 | Pubmed ID: 20374001
Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies.
Biochemical and biophysical research communications Jul, 2010 | Pubmed ID: 20617558
An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus.
Virology journal , 2010 | Pubmed ID: 20624292
Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies.
Biochemical and biophysical research communications Jun, 2010 | Pubmed ID: 20685351
Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant.
Vaccine Oct, 2010 | Pubmed ID: 20732469
Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients.
Virology journal , 2010 | Pubmed ID: 21047436
Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines.
Protein & cell Apr, 2010 | Pubmed ID: 21203946
A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses.
PloS one , 2011 | Pubmed ID: 21304591
Complement inhibition alleviates paraquat-induced acute lung injury.
American journal of respiratory cell and molecular biology Oct, 2011 | Pubmed ID: 21421909
CL-385319 inhibits H5N1 avian influenza A virus infection by blocking viral entry.
European journal of pharmacology Jun, 2011 | Pubmed ID: 21536025
ÜBER JoVE
Copyright © 2024 MyJoVE Corporation. Alle Rechte vorbehalten